Rockefeller Capital Management L.P. Clovis Oncology, Inc. Transaction History

Rockefeller Capital Management L.P.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Mar 06, 2023	SELL	$0.05 - $1.3 $300 - $7,800	-6,000 Reduced 94.12%	375 $0
Q3 2022 Nov 02, 2022	BUY	$1.05 - $2.85 $2,100 - $5,700	2,000 Added 45.71%	6,375 $7,000
Q2 2022 Aug 12, 2022	SELL	$0.63 - $2.96 $708 - $3,330	-1,125 Reduced 20.45%	4,375 $7,000
Q1 2022 May 13, 2022	SELL	$1.43 - $3.14 $715 - $1,570	-500 Reduced 8.33%	5,500 $11,000
Q4 2021 Feb 14, 2022	SELL	$2.7 - $4.76 $10,800 - $19,040	-4,000 Reduced 40.0%	6,000 $16,000
Q3 2021 Nov 12, 2021	SELL	$4.06 - $5.8 $31,667 - $45,240	-7,800 Reduced 43.82%	10,000 $44,000
Q2 2021 Aug 10, 2021	BUY	$5.02 - $7.05 $21,585 - $30,315	4,300 Added 31.85%	17,800 $103,000
Q1 2021 May 11, 2021	BUY	$4.81 - $10.34 $60,961 - $131,049	12,674 Added 1534.38%	13,500 $94,000
Q4 2020 Feb 12, 2021	BUY	$4.13 - $6.41 $1,346 - $2,089	326 Added 65.2%	826 $3,000
Q4 2019 Feb 07, 2020	BUY	$3.0 - $16.43 $1,500 - $8,215	500 New	500 $5,000
Q1 2019 May 10, 2019	SELL	$17.66 - $30.28 $0 - $0	0 Closed	0 $0
Q4 2018 Feb 12, 2019	BUY	$11.63 - $32.67 $0 - $0	0 New	0 $0

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.